Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease.

Martín-Gutiérrez, Nerea; Sánchez-Hernández, José Germán; Rebollo, Noemí; Pordomingo, Alejandra F; Muñoz, Fernando; Otero, María José

Martín-Gutiérrez, Nerea; Sánchez-Hernández, José Germán; Rebollo, Noemí; Pordomingo, Alejandra F; Muñoz, Fernando; Otero, María José.

Affiliation

Martín-Gutiérrez N; Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain.
Sánchez-Hernández JG; Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain jgermansh@gmail.com.
Rebollo N; Biomedical Research Institute of Salamanca, Salamanca, Salamanca, Spain.
Pordomingo AF; Pharmacy Service, University Hospital of Salamanca, Salamanca, Spain.
Muñoz F; Biomedical Research Institute of Salamanca, Salamanca, Salamanca, Spain.
Otero MJ; Biomedical Research Institute of Salamanca, Salamanca, Salamanca, Spain.

Eur J Hosp Pharm ; 29(4): 222-227, 2022 07.

Article in En | MEDLINE | ID: mdl-33115797

Subject(s)

Biosimilar Pharmaceuticals; Inflammatory Bowel Diseases; Adult; Antibodies, Monoclonal; Biosimilar Pharmaceuticals/adverse effects; Drug Substitution; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases/chemically induced; Inflammatory Bowel Diseases/drug therapy; Infliximab/therapeutic use; Prospective Studies

Key words

digestive system Diseases; drug monitoring; evidence-based medicine; hospital; inflammatory bowel diseases; pharmacy service

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Biosimilar Pharmaceuticals Type of study: Observational_studies Limits: Adult / Humans Language: En Journal: Eur J Hosp Pharm Year: 2022 Document type: Article Affiliation country: Spain Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google